Vaccine

Significant advancements and a fifteen-month extension for the RBDCOV project

2024

The European Commission has granted a fifteen-month extension to continue with the RBDCOV Project. So far, 240 volunteers have been recruited across all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy,

Read More

Significant advancements and fifteen month extension for the RBDCOV project

2024

The European Commission has granted a 15-month extension to the RBDCOV project, allowing researchers additional time to recruit volunteers for the HH-3 clinical trial. This trial assesses the efficacy,

Read More

Science4Pandemics initiatives to educate young people on pandemic preparedness

2023

Science4Pandemics (S4P) is an EU-funded project that aims to educate young people on how to prevent future pandemics through a game-based learning approach.

S4P needs your support!

Read More

Study reveals moderate effectiveness of Pfizer-BioNTech’s Covid-19 vaccine against Omicron in children aged 5-11

2022

A large study on the effectiveness of the Pfizer-BioNTech’s Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine.

The study was conducted at Israel’s largest healthcare organization, 

Read More

🇬🇧 Study reveals moderate effectiveness of Pfizer Covid-19 vaccine against Omicron in children aged 5-11

2022

Padua, 30 June 2022 – A large study on the effectiveness of the Pfizer Covid-19 vaccine in children aged 5-11 was published in 

Read More

🇬🇧 European RBDCOV project to study HIPRA’s COVID-19 vaccine in children adolescents and immunocompromised patients

2022

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.

Read More

Johnson & Johnson has planned trials of its vaccine that will include infants.

2021

Johnson & Johnson plans to test its coronavirus vaccine in infants and even in newborns, as well as in pregnant women and in people who have compromised immune systems.

Read More

Prof. Timo Vesikari talks to us about COVID-19 vaccines and children

2021

In December 2020 Penta held its annual Scientific Meeting. Despite the unusual get together due to COVID-19, we shared great science together. Among the experts invited was Timo Vesikari, a vaccine specialist who provided an insightful overview of the current scenario around COVID-19 vaccine development.

Read More